Literature DB >> 31884386

Complement fragments are biomarkers of antibody-mediated endothelial injury.

Erik Stites1, Brandon Renner1, Jennifer Laskowski1, Moglie Le Quintrec2, Zhiying You1, Brian Freed3, James Cooper1, Diana Jalal4, Joshua M Thurman5.   

Abstract

Antibody-mediated rejection (AbMR) adversely affects long-term graft survival in kidney transplantation. Currently, the diagnosis of AbMR requires a kidney biopsy, and detection of complement C4d deposition in the allograft is one of the diagnostic criteria. Complement activation also generates several soluble fragments which could potentially provide non-invasive biomarkers of the process. Furthermore, microvesicles released into the plasma from injured cells can serve as biomarkers of vascular injury. To explore whether soluble complement fragments or complement fragments bound to endothelial microvesicles can be used to non-invasively detect AbMR, we developed an in vitro model in which human endothelial cells were exposed to anti-HLA antibodies and complement sufficient serum. We found that complement fragments C4a and sC5b-9 were increased in the supernatants of cells exposed to complement-sufficient serum compared to cells treated complement-deficient serum. Furthermore, complement activation on the cell surface was associated with the release of microvesicles bearing C4 and C3 fragments. We next measured these analytes in plasma from kidney transplant recipients with biopsy-proven acute AbMR (n = 9) and compared the results with those from transplant recipients who also had impaired allograft function but who did not have AbMR (n = 30). Consistent with the in vitro results, complement fragments C4a and Ba were increased in plasma from patients with AbMR compared to control subjects (P < 0.001 and P < 0.01, respectively). Endothelial microvesicle counts were not increased in patients with AbMR, however, and the number of microvesicles with C4 and C3 bound to the surface was actually lower compared to control subjects (both P < 0.05). Our results suggest that plasma complement activation fragments may be useful as non-invasive biomarkers of antibody-mediated complement activation within the allograft. Complement-opsonized endothelial microvesicles are decreased in patients with AbMR, possibly due to enhanced clearance of microvesicles opsonized with C3 and C4 fragments.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody mediated rejection; Biomarker; Complement; Donor specific antibody

Mesh:

Substances:

Year:  2019        PMID: 31884386      PMCID: PMC7192552          DOI: 10.1016/j.molimm.2019.12.011

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  34 in total

1.  C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings.

Authors:  M Haas; M H Rahman; L C Racusen; E S Kraus; S M Bagnasco; D L Segev; C E Simpkins; D S Warren; K E King; A A Zachary; R A Montgomery
Journal:  Am J Transplant       Date:  2006-08       Impact factor: 8.086

2.  Plasma C4d+ Endothelial Microvesicles Increase in Acute Antibody-Mediated Rejection.

Authors:  Cindy M Tower; Morayma Reyes; Karen Nelson; Nicolae Leca; Niamh Kieran; Kimberly Muczynski; Jonathan A Jefferson; Christopher Blosser; Aleksandra Kukla; David Maurer; Wayne Chandler; Behzad Najafian
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

Review 3.  An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts.

Authors:  Mark Haas
Journal:  Curr Opin Organ Transplant       Date:  2014-06       Impact factor: 2.640

4.  The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.

Authors:  C A Schinstock; F Cosio; W Cheungpasitporn; D M Dadhania; M J Everly; M D Samaniego-Picota; L Cornell; M D Stegall
Journal:  Am J Transplant       Date:  2017-01-25       Impact factor: 8.086

5.  In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease.

Authors:  Chantal M Boulanger; Nicolas Amabile; Alain P Guérin; Bruno Pannier; Aurélie S Leroyer; Clément Nguyen Ziad Mallat; Alain Tedgui; Gérard M London
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

6.  The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody.

Authors:  P F Halloran; J Schlaut; K Solez; N S Srinivasa
Journal:  Transplantation       Date:  1992-03       Impact factor: 4.939

7.  C3D deposition in peritubular capillaries indicates a variant of acute renal allograft rejection characterized by a worse clinical outcome.

Authors:  Dirk R J Kuypers; Evelyne Lerut; Pieter Evenepoel; Bart Maes; Yves Vanrenterghem; Boudewijn Van Damme
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

8.  Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Authors:  Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

Review 9.  Complement System Part I - Molecular Mechanisms of Activation and Regulation.

Authors:  Nicolas S Merle; Sarah Elizabeth Church; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

10.  The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

Authors:  M Haas; A Loupy; C Lefaucheur; C Roufosse; D Glotz; D Seron; B J Nankivell; P F Halloran; R B Colvin; Enver Akalin; N Alachkar; S Bagnasco; Y Bouatou; J U Becker; L D Cornell; J P Duong van Huyen; I W Gibson; Edward S Kraus; R B Mannon; M Naesens; V Nickeleit; P Nickerson; D L Segev; H K Singh; M Stegall; P Randhawa; L Racusen; K Solez; M Mengel
Journal:  Am J Transplant       Date:  2018-01-21       Impact factor: 8.086

View more
  5 in total

Review 1.  COVID‑19 and ischemic stroke: Mechanisms of hypercoagulability (Review).

Authors:  Shuoqi Zhang; Jinming Zhang; Chunxu Wang; Xiaojing Chen; Xinyi Zhao; Haijiao Jing; Huan Liu; Zhuxin Li; Lihua Wang; Jialan Shi
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

Review 2.  The complement system in pediatric acute kidney injury.

Authors:  Erin K Stenson; Jessica Kendrick; Bradley Dixon; Joshua M Thurman
Journal:  Pediatr Nephrol       Date:  2022-10-06       Impact factor: 3.651

3.  Extracellular vesicles derived from patients with antibody-mediated rejection induce tubular senescence and endothelial to mesenchymal transition in renal cells.

Authors:  Rossana Franzin; Alessandra Stasi; Fabio Sallustio; Stefania Bruno; Guido Merlotti; Marco Quaglia; Giuseppe Grandaliano; Paola Pontrelli; Joshua M Thurman; Giovanni Camussi; Giovanni Stallone; Vincenzo Cantaluppi; Loreto Gesualdo; Giuseppe Castellano
Journal:  Am J Transplant       Date:  2022-07-05       Impact factor: 9.369

Review 4.  Recent Advances on Biomarkers of Early and Late Kidney Graft Dysfunction.

Authors:  Marco Quaglia; Guido Merlotti; Gabriele Guglielmetti; Giuseppe Castellano; Vincenzo Cantaluppi
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

Review 5.  Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement.

Authors:  Kurt R Stenmark; Maria G Frid; Evgenia Gerasimovskaya; Hui Zhang; Mary K McCarthy; Joshua M Thurman; Thomas E Morrison
Journal:  Pulm Circ       Date:  2021-05-18       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.